Benjamin F. Edwards & Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Benjamin F. Edwards & Company’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-392	Closed	-$6K	–	1151
2016 Q1	$6K	Sell	392 -762	-66%	-$13.3K	﹤0.01%	906
2015 Q4	$25K	Buy	1,154 +191	+20%	+$3.72K	0.01%	646
2015 Q3	$19K	Sell	963 -81	-8%	-$2.56K	﹤0.01%	740
2015 Q2	$36K	Buy	1,044 +46	+5%	+$1.4K	0.01%	663
2015 Q1	$26K	Buy	998 +528	+112%	+$9.68K	0.01%	706
2014 Q4	$6K	Buy	+470	New	+$5.88K	﹤0.01%	883
2014 Q1	–	Sell	-1,350	Closed	-$10K	–	997
2013 Q4	$10K	Buy	+1,350	New	+$7.28K	﹤0.01%	664
2013 Q3	–	Sell	-2,000	Closed	-$5K	–	875
2013 Q2	$5K	Buy	+2,000	New	+$4.8K	﹤0.01%	678

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Benjamin F. Edwards & Company's HZNP Position: Q2 2016 in Review

Benjamin F. Edwards & Company sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 392 shares — an estimated $6K sold.

Benjamin F. Edwards & Company first reported a position in HZNP in Q2 2013 and held it in 8 quarters. The position peaked at $36K in Q2 2015. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

Benjamin F. Edwards & Company reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
Benjamin F. Edwards & Company sold 392 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $6K.
Benjamin F. Edwards & Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 8 quarters.
Benjamin F. Edwards & Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $36K in Q2 2015.
198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2016, filed 11 Jul 2016.